Partnerships
Further unlock the value of the ImmTOR™ platform
Our Partnerships
Selecta has entered into strategic transactions with leading biopharmaceutical companies to further unlock the value of the ImmTORTM platform.
Immtor Approach
Agreement
Indications
2020
Immtor Approach
ENABLE RE-DOSING OF LIFE-SAVING GENE THERAPY
Agreement
Research Option and License Agreement (Global)
Indications
Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophy subtypes
2020
Immtor Approach
IMPROVING THE EFFICACY OF BIOLOGICS
Agreement
License Agreement (Global, excluding China)
Indications
Chronic refractory gout
2019
Immtor Approach
ENABLE RE-DOSING OF LIFE-SAVING GENE THERAPY
Agreement
License Agreement (Global)
Indications
Pompe disease
2019
Immtor Approach
ENABLE RE-DOSING OF LIFE-SAVING GENE THERAPY
Agreement
50/50 Collaboration Agreement
Indications
Methylmalonic acidemia and other undisclosed indications
Why we partner
While advancing our own programs, the broad applicability of the ImmTORTM platform gives us the unique ability to address immunogenicity across a range of indications and in combination with a variety of therapeutic approaches. As such, we believe that the best way to use our ImmTORTM platform to help the largest number of patients is to develop strategic partnerships, research collaborations and licensing arrangements.
We are open to discussing opportunities both for partners to use our ImmTOR platform for their own therapies as well as for us to bring therapies in house on our own to optimize with ImmTOR.
Partner with us
Connect with us about partnership opportunities
We are open to discussing opportunities both for partners to use our ImmTOR platform for their own therapies as well as for Selecta to bring therapies in house on our own to optimize with ImmTOR.
